EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity

Yan Q Chen iD, Ye Yang iD, Eugene Y Zhen iD, Thomas P Beyer, Hongxia Li, Yi Wen, Mariam Ehsani iD, Nicholas Jackson, Katherine Xie, Hyesoo Jung iD, Julia L Scheithauer, Anni Kumari iD und 9 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2322332121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Yan Q Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 462585. Hauptthemen laut MEDLINE: Lipoprotein Lipase, Apolipoproteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute, Fondation Leducq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apolipoprotein AV (APOA5) lowers plasma triglyceride (TG) levels by binding to the angiopoietin-like protein 3/8 complex (ANGPTL3/8) and suppressing its capacity to inhibit lipoprotein lipase (LPL) catalytic activity and its ability to detach LPL from binding sites within capillaries. However, the sequences in APOA5 that are required for suppressing ANGPTL3/8 activity have never been defined. A clue to the identity of those sequences was the presence of severe hypertriglyceridemia in two patients harboring an APOA5 mutation that truncates APOA5 by 35 residues (“APOA5Δ35”). We found that wild-type (WT) human APOA5, but not APOA5Δ35, suppressed ANGPTL3/8’s ability to inhibit LPL catalytic activity. To pursue that finding, we prepared a mutant mouse APOA5 protein lacking 40 C-terminal amino acids (“APOA5Δ40”). Mouse WT-APOA5, but not APOA5Δ40, suppressed ANGPTL3/8’s capacity to inhibit LPL catalytic activity and sharply reduced plasma TG levels in mice. WT-APOA5, but not APOA5Δ40, increased intracapillary LPL levels and reduced plasma TG levels in Apoa5 −/− mice (where TG levels are high and intravascular LPL levels are low). Also, WT-APOA5, but not APOA5Δ40, blocked the ability of ANGPTL3/8 to detach LPL from cultured cells. Finally, an antibody against a synthetic peptide corresponding to the last 26 amino acids of mouse APOA5 reduced intracapillary LPL levels and increased plasma TG levels in WT mice. We conclude that C-terminal sequences in APOA5 are crucial for suppressing ANGPTL3/8 activity in vitro and for regulating intracapillary LPL levels and plasma TG levels in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein LipaseApolipoproteinsMiceHumansAnimalsAngiopoietin-like ProteinsAngiopoietin-Like Protein 3Amino AcidsTriglyceridesApolipoprotein A-V

Stichwörter der Autor:innen

ANGPTL3/8apolipoprotein AVlipoprotein lipasetriglycerides

Substanzen

Angiopoietin-like ProteinsLipoprotein LipaseApolipoproteinsAngiopoietin-Like Protein 3Amino AcidsTriglyceridesAPOA5 protein, humanApolipoprotein A-VANGPTL3 protein, human

Autor:innen und Institutionen

  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 462585.
  • Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
  • Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
  • Finsen Laboratory, Centre for Cancer and Organ Diseases, Copenhagen University Hospital-Rigshospitalet, DK-2200 Copenhagen N, Denmark.
  • Finsen Laboratory, Biotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen N, Denmark.
  • Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215.

ORCID-Profile: Yan Q Chen, Ye Yang, Eugene Y Zhen, Mariam Ehsani, Hyesoo Jung, Anni Kumari, Gabriel Birrane, Robert W Siegel, Yuewei Qian, Michael Ploug, Stephen G Young, Robert J Konrad

Förderung

  • NHLBI NIH HHS
  • HHS | NIH | National Heart, Lung, and Blood Institute
  • Fondation Leducq
  • Eli Lilly and Company

Zitieren

APA

Chen, Y. Q., Yang, Y., Zhen, E. Y., Beyer, T. P., Li, H., Wen, Y., Ehsani, M., Jackson, N., Xie, K., Jung, H., Scheithauer, J. L., Kumari, A., Birrane, G., Russell, A. M., Balasubramaniam, D., Liao, Z., Siegel, R. W., Qian, Y., Ploug, M., …, & Konrad, R. J. (2024). Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2322332121

Vancouver

Chen YQ, Yang Y, Zhen EY, Beyer TP, Li H, Wen Y, et al. Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2322332121

BibTeX
@article{Chen2024,
  author = {Chen, Yan Q and Yang, Ye and Zhen, Eugene Y and Beyer, Thomas P and Li, Hongxia and Wen, Yi and Ehsani, Mariam and Jackson, Nicholas and Xie, Katherine and Jung, Hyesoo and Scheithauer, Julia L and Kumari, Anni and Birrane, Gabriel and Russell, Anna M and Balasubramaniam, Deepa and Liao, Zhongping and Siegel, Robert W and Qian, Yuewei and Ploug, Michael and Young, Stephen G and Konrad, Robert J},
  title = {Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2322332121}
}
Kostenlos starten →